Clareo Health | A Study of the Effectiveness And Safety Of Lidoderm® As Add-On Treatment in Patients With Postherpetic Neuralgia, Diabetic Neuropathy, or Low Back Pain
A Study of the Effectiveness And Safety Of Lidoderm® As Add-On Treatment in Patients With Postherpetic Neuralgia, Diabetic Neuropathy, or Low Back Pain
Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Endo USA Inc., a Keenova Therapeutics Company
Age
18–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Were currently receiving an analgesic regimen that contained gabapentin
Had been on a stable dose of gabapentin for at least 14 days (same dose ±10% for 14 days)
Had a partial response to a gabapentin-containing analgesic regimen defined as an average daily pain intensity score of \>4 on a ) to 10 scale, with 0 being no pain and 10 being pain as bas as the patients have ever imagined (Question 5 of the Brief Pain Inventory \[BPI\] within 24 hours prior to the screening visit
For diabetic patients, had a hemoglobin A1c level \<0.13 (normal range, 0.047-0.064)
You may not be if
Had a neurological condition other than that associated with their pain diagnosis that, in the opinion of the investigator, would have interfered with their ability to participate in the study
Had received an epidural steroid/local anesthetic injection within 14 days prior to study entry
Had received trigger point injections within 14 days prior to study entry
Had received Botox injections within 3 months prior to study entry
Were taking a lidocaine-containing product that could not be discontinued while receiving Lidoderm
Were taking Class 1 anti-arrhythmic drugs (e.g., mexiletine, tocainide)
